Physician profile
Ravinder Bhalla
NPI 1841214566
$125,032.23
in general payments reported to CMS, 2019-2025
27 companies · $6,945 in 2025
The $6,945 reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,842 · 2020: $15K · 2021: $22K · 2022: $21K · 2023: $39K · 2024: $15K · 2025: $6,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $7,666 · Consulting Fee: $4,100 · Travel and Lodging: $512 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,400.00 |
| Food and Beverage | $7,666.44 |
| Consulting Fee | $4,100.00 |
| Travel and Lodging | $512.17 |
| Education | $116.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $88,445.45 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $11,598.43 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Allergan, INC. | $7,758.12 | 2019-2020 | |
| Abbvie INC. | $6,870.54 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,503.56 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,267.09 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $1,229.09 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,123.93 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $698.70 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $676.05 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $495.65 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $375.34 | 2021-2024 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $144.89 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $107.63 | 2023 | Epclusa |
| Ironshore Pharmaceuticals INC. | $103.63 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $90.32 | 2020 | |
| Axsome Therapeutics, INC. | $75.07 | 2023 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.48 | 2020-2022 | |
| Indivior INC. | $46.40 | 2022-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $41.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.27 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $15.72 | 2024 | Cobenfy |
| Tris Pharma INC | $14.83 | 2024 | Onyda Xr |
| Eisai INC. | $12.93 | 2022 | |
| Almatica Pharma LLC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.